COVID-19 and Childhood Cancer

NCT06482281 | Active Not Recruiting

• 1 other identifier: 2022-06312
• Study Type: observational
• Target: 100,000
• Locations: 1 country
• Sites: 1

Brief Summary

The investigators will first examine the impact of the COVID-19 pandemic on childhood cancer patients in Sweden and Denmark, both regarding susceptibility to severe COVID-19 among long-term childhood cancer survivors, and, for those diagnosed with childhood cancer during the pandemic, whether the path through primary care to cancer diagnosis as well as short-term survival has changed. Second, the investigators will study childhood cancer incidence before, during and after the pandemic with the particular aim to test the hypothesis regarding an infectious disease etiology for acute lymphoblastic leukemia.

Conditions

COVID-19; Childhood Cancer; Childhood Leukemia, Acute Lymphoblastic

Keywords

Childhood Cancer; Childhood Cancer Incidence; Childhood Cancer Survival; Childhood Leukemia, Acute Lymphoblastic; Cohort Study; Register Study

Outcome Measures

Primary Outcomes (4)

• Severe COVID-19

  Defined as: * death with COVID-19 listed as a cause of death * hospitalization, or admission to intensive care unit, because of COVID-19 (main diagnosis) or respiratory problems (main diagnosis) AND COVID-19 as secondary diagnosis

  Up to 3 years

• Childhood cancer survival

  Overall survival after a childhood cancer diagnosis

  After three and twelve months after the cancer diagnosis and three years after cancer diagnosis

• Number of contacts before childhood cancer diagnosis

  Number of healthcare contacts (including primary care) the year before the cancer diagnosis

  One year before cancer diagnosis

• Childhood cancer incidence

  Age standardized incidence rates for childhood cancer and cancer subtypes (particularly acute lymphoblastic leukemia) in Sweden and Denmark during and after the pandemic and compare it to the 5 years preceding the pandemic

  From 2015

Study Arms (4)

Childhood cancer survivors

Childhood cancer cases (0-19 years old) reported to the national cancer registers from 1971 in Sweden and Denmark, who were alive five years after the cancer diagnosis

Matched comparisons

Five general population comparisons were randomly selected and matched to the childhood cancer survivors by sex and year of birth

Siblings

All siblings of the childhood cancer survivors

Childhood cancer cases

Childhood cancer cases (0-19 years old) reported to the national cancer registers from 2015 in Sweden and Denmark. They will then further divided in three groups: before the pandemic (2015-2019), during the pandemic (2020-2022), and after the pandemic (2022-)

Eligibility Criteria

• Age: 0 Years - 19 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

* Childhood cancer cases (age 0-19) diagnosed from 1971 in Sweden and Denmark who were alive five years after diagnosis + their matched comparisons AND all siblings of the childhood cancer survivors * All children (age 0-19) diagnosed with cancer from 2015 in Sweden and Denmark

You may qualify if:

• Childhood cancer cases (age 0-19) diagnosed from 1971 in Sweden and Denmark who were alive five years after diagnosis
• Two different comparisons groups: five age- and sex-matched comparisons for each childhood cancer survivor as well as all siblings of the childhood cancer survivors.
• All childhood cancer survivors, matched comparisons, and siblings of the survivors should be 20+ at the start of 2020.
• \- All children (age 0-19) diagnosed with cancer from 2015 in Sweden and Denmark

Sponsors & Collaborators

• Karolinska Institutet: lead
• The Swedish Research Council: collaborator
• The Swedish Childhood Cancer Fund: collaborator

Study Sites (1)

Karolinska Institutet

Stockholm, 17177, Sweden

Location

MeSH Terms

Conditions

COVID-19; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Leukemia, Lymphoid; Leukemia; Neoplasms by Histologic Type; Hematologic Diseases; Hemic and Lymphatic Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Giorgio Tettamanti, PhD

  Karolinska Institutet

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Senior research specialist, Docent

Study Record Dates

• First Submitted: June 28, 2024
• First Posted: July 1, 2024
• Study Start: January 1, 2023
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: July 3, 2024

Record last verified: 2024-07

Data Sharing

• IPD Sharing: Will not share

Locations

SE (1)